|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-4-13
|
|
pubmed:abstractText |
We previously reported a beneficial effect of benfluorex (BFL) on oral glucose tolerance test (OGTT) and visceral fat mass in an open-label study conducted in 60 HIV-infected patients. The objective of this study was to assess whether administration of BFL compared to placebo (PBO) improves insulin resistance (IR) in HIV+ patients with HAART- induced lipodystrophy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1528-4336
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
33-40
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19362994-Adult,
pubmed-meshheading:19362994-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:19362994-Double-Blind Method,
pubmed-meshheading:19362994-Female,
pubmed-meshheading:19362994-Fenfluramine,
pubmed-meshheading:19362994-Glucose Intolerance,
pubmed-meshheading:19362994-HIV-1,
pubmed-meshheading:19362994-HIV-Associated Lipodystrophy Syndrome,
pubmed-meshheading:19362994-Humans,
pubmed-meshheading:19362994-Hypolipidemic Agents,
pubmed-meshheading:19362994-Insulin,
pubmed-meshheading:19362994-Insulin Resistance,
pubmed-meshheading:19362994-Male,
pubmed-meshheading:19362994-Middle Aged,
pubmed-meshheading:19362994-Treatment Outcome
|
|
pubmed:articleTitle |
A randomized, double-blind, placebo-controlled study of benfluorex in HIV-infected patients with insulin resistance or impaired glucose tolerance.
|
|
pubmed:affiliation |
CISIH-SUD Clinical Research Department, Pôle Oncologie Spécialités Médicales et Chirurgicales, CHU Sainte-Marguerite, APHM, Marseille, France. isabelle.poizot@mail.ap-hm.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
